Active Not Recruiting
PHASE2
INTERVENTIONAL
NCT06409130
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
Interventions
Name:
NNC0194-0499
Type:
DRUG
Description:
Administered subcutaneously.
Name:
Semaglutide
Type:
DRUG
Description:
Administered subcutaneously.
Name:
NNC0194-0499 placebo
Type:
DRUG
Description:
Administered subcutaneously.
Name:
Semaglutide placebo (Group A)
Type:
DRUG
Description:
Administered subcutaneously.
Name:
Cagrilintide + semaglutide
Type:
DRUG
Description:
Administered subcutaneously.
Name:
Cagrilintide
Type:
DRUG
Description:
Administered subcutaneously.
Name:
Cagrilintide placebo
Type:
DRUG
Description:
Administered subcutaneously.
Name:
Semaglutide placebo (Group B)
Type:
DRUG
Description:
Administered subcutaneously.
Primary Outcomes
Measure:
Change in Enhanced Liver Fibrosis (ELF)
TimeFrame:
From week 0 to week 28
Description:
Measured as logarithm score
Trial Information
NCT ID
NCT06409130
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025